Moreover, despite promising effects of VEGF therapy on tumor angiogenesis, serious adverse effects on cardiovascular events (angina pectoris, arterial thrombosis, cerebral- or myocardial ischemia and infarction) have been shown for the VEGF-A inhibitor bevacizumab (114). This evidence concerns the gene VEGFA and angina pectoris.